Clinical Trials Logo

Secondary Hyperparathyroidism clinical trials

View clinical trials related to Secondary Hyperparathyroidism.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT01725113 Terminated - Kidney Failure Clinical Trials

Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol

ECRIP
Start date: November 2012
Phase: Phase 4
Study type: Interventional

The purpose of this non-inferiority study is to compare the safety and effectiveness of a mineral and bone disease treatment protocol based on calcitriol to one based on paricalcitol in hemodialysis patients using revised Kidney Disease: Improving Global Outcomes (KDIGO) parathyroid hormone targets.

NCT ID: NCT01576146 Terminated - Clinical trials for Secondary Hyperparathyroidism

Open-label Study to Assess the Long-term Safety and Efficacy of AMG 416 (Also Known as KAI-4169) in Patients With Secondary Hyperparathyroidism

Start date: March 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the long term safety and efficacy of thrice weekly intravenous (IV) administration of KAI-4169 in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis subjects.

NCT ID: NCT01277510 Terminated - Clinical trials for Chronic Kidney Disease

Pediatric Chronic Kidney Disease Safety and Efficacy

Start date: June 28, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of adding cinacalcet to the current treatment of secondary hyperparathyroidism in children currently receiving dialysis compared to a treatment regimen that does not include cinacalcet.

NCT ID: NCT01134315 Terminated - Clinical trials for End-Stage Renal Disease

Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice

Start date: June 2010
Phase: N/A
Study type: Observational

The objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (SHPT). Participants were to be followed for a minimum of 3 months and up to approximately 36 months to monitor the incidence of hypercalcemia (high calcium levels in blood).

NCT ID: NCT01012414 Terminated - Clinical trials for Coronary Artery Disease

Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease

VINCA-CKD
Start date: January 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if vitamin D supplementation changes the results of certain tests associated with inflammation in the body using an oral, synthetic form of vitamin D called paricalcitol.

NCT ID: NCT00664430 Terminated - Clinical trials for Secondary Hyperparathyroidism

Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects

Start date: January 2009
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to evaluate the efficacy and safety of paricalcitol in participants with moderate to severe secondary hyperparathyroidism (SHPT) undergoing hemodialysis who are resistant to treatment with calcitriol.

NCT ID: NCT00469599 Terminated - Clinical trials for Chronic Kidney Disease

Treatment of Secondary Hyperparathyroidism in the Uremic Patient

Start date: July 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to compare alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.

NCT ID: NCT00446329 Terminated - Clinical trials for Secondary Hyperparathyroidism

Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

Start date: July 2006
Phase: Phase 4
Study type: Interventional

The 1st phase of the study will assess the acute biochemical response of PTH, calcium and phosphorus to orally administered doses of cinacalcet once (60mg) or twice (30mg x 2) per day. The 2nd phase of the study designed to evaluate the long term effects of cinacalcet on BMD (bone mineral density)and the levels of PTH, calcium, phosphorus as well as its ability to control secondary hyperparathyroidism without simultaneous administration of other vitamin D compounds.

NCT ID: NCT00415584 Terminated - Clinical trials for Secondary Hyperparathyroidism

Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

Start date: January 2007
Phase: Phase 1/Phase 2
Study type: Interventional

Secondary hyperparathyroidism can persist following successful renal transplantation and can cause high blood calcium, kidney dysfunction or failure and excessive bone loss among other problems. If the condition does not resolve, surgery is frequently required to remove the parathyroid glands, with all the inherent risks of surgery. Cinacalcet, a medicine used to treat secondary hyperparathyroidism in patients with kidney disease, may be effective in treating this condition in the renal transplant recipient. We will study the effect of cinacalcet on calcium, bone and renal function in a 6 month treatment protocol.

NCT ID: NCT00175149 Terminated - Clinical trials for Chronic Kidney Disease

Active Vitamin D Effect on Left Ventricular Hypertrophy

Start date: January 2002
Phase: Phase 4
Study type: Interventional

Left ventricular hypertrophy (LVH) predicts mortality at start of dialysis. Prevention of of LVH is important. It is not known whether secondary hyperparathyroidism might induce LVH. In the present study patients are randomised to 1.25 dihydroxycholecalciferol or no treatment to study the effect on LVH.